[{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AT04A","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ AC Immune"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Affiris","sponsor":"Frontier Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Affitope AT04","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affiris \/ Frontier Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Frontier Biotechnologies"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"mAB C6-17","moa":"Mutant huntingtin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Affiris \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Affiris

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the lic...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 22, 2021

                          Lead Product(s) : Affitope AT04,Aluminium Oxyhydroxide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Frontier Biotechnologies

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : $5.0 million

                          July 27, 2021

                          Lead Product(s) : PD01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : AC Immune

                          Deal Size : $100.8 million

                          Deal Type : Acquisition

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : AFFITOPE® peptide vaccine candidates AT04A and AT06A are safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response in the cardiovascular disease indication hypercholesterolemia.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 27, 2021

                          Lead Product(s) : AT04A

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2021

                          Lead Product(s) : mAB C6-17

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 27, 2020

                          Lead Product(s) : PD01

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 02, 2016

                          Lead Product(s) : PD01A Vaccine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : University Hospital Tübingen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 02, 2015

                          Lead Product(s) : Affitope PD01A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 27, 2015

                          Lead Product(s) : Affitope AT04A

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Medical University of Vienna

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : PD01A Vaccine

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : University Hospital, Bordeaux | INSERM | Forschungszentrum Jülich | University Hospital, Toulouse

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 21, 2014

                          Lead Product(s) : PD01A Vaccine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : University Hospital, Bordeaux | INSERM | Forschungszentrum Jülich | University Hospital, Toulouse

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Affitope PD03A

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : PROSENEX AmbulatoriumbetriebsGMBH | Medical University Innsbruck | Forschungszentrum Jülich

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 17, 2014

                          Lead Product(s) : Affitope PD03A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : PROSENEX AmbulatoriumbetriebsGMBH | Medical University Innsbruck | Forschungszentrum Jülich

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank